HENLIUS (02696.HK): Included in Stock Connect eligible securities list effective 7 September
NewTimeSpace News: On 7 September 2026, Shanghai Henlius Biotech, Inc. (stock code: 02696) voluntarily announced that, pursuant to the "Notice on the Adjustment of Eligible Securities under the Shanghai-Hong Kong Stock Connect" and the "Announcement on the Adjustment of the Eligible Securities List under the Shenzhen-Hong Kong Stock Connect" published by the Shanghai Stock Exchange and the Shenzhen Stock Exchange respectively, the Company has been included in the eligible securities lists under the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect, formally effective from 7 September 2026.
The Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect are channels for stock trading and investment between investors in Hong Kong and Mainland China's capital markets. The inclusion of the Company in the eligible securities lists under Stock Connect will help broaden its shareholder base and enhance the trading liquidity of its shares, thereby further improving its investment value in the capital markets.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- New round of southbound Stock Connect target adjustments: 54 added, 15 removed
- HENLIUS (02696.HK): Added as Hang Seng Composite Index Constituent, Effective 7 September
- Going Global Weekly Report: Pharma Overseas Expansion Blossoms Across Fronts, A-Share Companies Accelerate Hong Kong Listings - 20260821
- HENLIUS (02696.HK): enters global strategic partnership with Sandoz covering up to 10 biosimilar products, with upfront and milestone payments totaling up to USD 314 million
- Henlius (02696.HK): NMPA Approves Clinical Trial Application for HLX43 Combined with Bevacizumab in Solid Tumors